

## Format for ANSWERING REVIEWERS

July 05, 2015

Dear Xiu-Xia Song, Science Editor,



Please find enclosed the edited manuscript in Word format (file name: 17216-revised manuscript.doc).

**Title:** Liver Transplantation in a Patient with Primary Antiphospholipid Syndrome and Budd-Chiari Syndrome.

**Author:** Tatyana M. Reshetnyak, Natalia V. Seredavkina, Maria A. Satybaldyeva, Evgeniy L. Nasonov, Vasily I. Reshetnyak

**Name of Journal:** *World Journal of Hepatology*

**ESPS Manuscript NO:** 17216

The manuscript has been improved according to the suggestions of reviewers:

1. Format has been updated (correction of text was yellow color highlighted)

2. Revision has been made according to the suggestions of the reviewers:

(1 – reviewer **02997961**) Thank you so much for the important work undertaken on the review and for your appreciation of our manuscript.

(2 – reviewer **00012156**) Thank you very much for your review on our manuscript. Actually, literature on the use of dabigatran etexilate (DE) for the treatment and prevention of venous thromboembolic events enough. However, there are few descriptions of the use of DE in patients with antiphospholipid syndrome (APS). We did not find any descriptions of the use of DE in patients with APS and with Budd-Chiari syndrome. Therefore, in presented case, we report about the first the successful use of dabigatran etexilate for prolonged anticoagulation therapy in APS patient with BDS after orthotopic liver transplantation.

(3 – reviewer **00068305**) Many thanks to the reviewer for the important work undertaken on the review and for your appreciation of our manuscript. We have corrected in the abstract Budd-Chiari syndrome (highlighted).

3. References and typesetting were corrected

Thank you again for publishing my manuscript in the *World Journal of Hepatology*.

Sincerely yours,

Vasily Ivanovich RESHETNYAK, MD, PhD, DSc, Professor;  
V.A. Negovsky Research Institute of General Reanimatology  
25-2, Petrovka St. Moscow 107031, Russian Federation,  
Tel./Fax: +7(495) 694-65-05 (Office);  
E-mail: [vasiliy.reshetnyak@yandex.ru](mailto:vasiliy.reshetnyak@yandex.ru)

**Reviewed by 02997961**

Case report well prepared. I think, This case report can open new horizons the Dabigatran etexilate for use of thrombophilic disorders. If a few letters error corrected. Abstract in the fourth line Budd-Chiari instead of Budd-Chiari should be written. I think, it can publish.

**Reviewed by 00012156**

Tatyana et al describe the usage Dabigatran etexilate for the liver transplant patient with primary antiphospholipid syndrome and Budd-Chiari Syndrome. The authors stated that this is the first report in which the Dabigatran etexilate was administered for the liver transplant patient. But there were only a few descriptions on the drug of Dabigatran etexilate in discussion. It is unclear what authors eager to assert. The description was desultory and should be much more compacted.

**Reviewed by 00068305**

no